IMU (ASX) The CF33, Vaxinia and Oncarlytics Deal

Originally posted by Harry58: ↑

Following the recent announcement on the 2nd November 2023, the Vaxinia MAST trial has been extended to a 16 cohort design in both monotherapy and combination with Pembrolizumab administered by intra-tumoral injection (IT) and intravenous infusion (IV)

The progress through this trial has been exceptional and well supported by oncologists across 12 recruiting sites. We are now in the final two cohorts in the combination therapy and with only two cohorts remaining in the monotherapy with no reporting of dose limiting toxicities for the 36 patients enrolled in the 12 cohorts to date.

As this is a dose escalation study with an estimated primary completion date of 31st December 2024 there is much interest in what will be the maximum tolerable dose.

There is scope to extend the number of cohorts beyond the current design.
The combination cohorts in both IT and IV administration could progress to 3x10^8 and the monotherapy cohorts could possibly test a 1x10^9 dose.
In the preclinical animal models, a six-log therapeutic index was established between 1000 and 1 billion virus particles.

As mentioned in an earlier post, the historic record for the efficacy of CF33 in human trials has already been written in the Abstract release of results from the recent ESMO 2023 conference in Madrid.
The conclusions were that CHECKvacc induces tumor infiltration of CD4+ and CD8+ T cells.
Upregulation of PD-L1 within the tumor microenvironment further suggests immune activation by CHECKvacc.

Note these results were based on a December 2022 data read out of the first three cohorts with a maximum dose of 1x10^6 or one million virus particles.

In the context of CF33, Vaxinia being the parental virus is more potent than CHECKvacc and in my view will reveal impressive effficacy when data undergoes third party review and results are published in medical journals.

The following data of the cohorts' commencement dates, dose levels and durations have been updated from a previous post and presented in free text to improve the visibility of information.

VAXINIA MAST
Mono IT Cohort 1 - Commenced 18/05/2022 Dose 1x10^6 Duration Days 166
Mono IT Cohort 2 - Commenced 31/10/2022 Dose 1x10^7 Duration Days 94
Mono IT Cohort 3 - Commenced 02/02/2023 Dose 3x10^7 Duration Days 62
Mono IT Cohort 4 - Commenced 04/09/2023 Dose 1x10^8 Duration Days In Progress 62
Mono IT Cohort 5 - Not Commenced Dose 3x10^8

Mono IV Cohort 1 - Commenced 23/09/2022 Dose 1x10^6 Duration Days 75
Mono IV Cohort 2 - Commenced 05/12/2022 Dose 1x10^7 Duration Days 59
Mono IV Cohort 3 - Commenced 02/02/2023 Dose 3x10^7 Duration Days 62
Mono IV Cohort 4 - Commenced 09/06/2023 Dose 1x10^8 Duration Days 147
Mono IV Cohort 5 - Commenced 02/11/2023 Dose 3x10^8 Duration Days In Progress 2

Comb IT Cohort 1 - Commenced 03/03/2023 Dose 1x10^7 Duration Days 185
Comb IT Cohort 2 - Commenced 04/09/2023 Dose 3x10^7 Duration Days In Progress 62
Comb IT Cohort 3 - Not Commenced Dose 1x10^8

Comb IV Cohort 1 - Commenced 03/03/2023 Dose 1x10^7 Duration Days 98
Comb IV Cohort 2 - Commenced 09/06/2023 Dose 3x10^7 Duration Days 147
Comb IV Cohort 3 - Commenced 02/11/2023 Dose 1x10^8 Duration Days In Progress 2

As has been mentioned by other posters, patience is required as the trial seeks out the optimal tolerable dose and hence establishes the optimal biological dose for the final extension cohort.

As always there is much to look forward to as the company progresses toward its application for a fast track registrational trial for Vaxinia.

A very big congratulations to Leslie and her team for the impressive progression of CF33 through clinical trials.

GLTAH - Go Team Imugene
.

Expand

A big thanks for posting that, a lot more detail.Where did you get this information from ?
I couldn’t see it on the website, or trial updates.
Is it from the weekends poster presentation ?

No.	Vol.	Price($)
12	1508773	1.3¢

No.

Vol.

Price($)

1508773

1.3¢

Price($)	Vol.	No.
1.4¢	10827552	40

Price($)

Vol.

No.

1.4¢

10827552

No.	Vol.	Price($)
13	2093388	0.013
28	9660596	0.012
30	13492277	0.011
108	26790571	0.010
38	19935780	0.009

No.

Vol.

Price($)

2093388

0.013

9660596

0.012

13492277

0.011

108

26790571

0.010

19935780

0.009

Price($)	Vol.	No.
0.014	10908722	39
0.015	8071485	27
0.016	6896037	29
0.017	7128221	13
0.018	1636332	11

Price($)

Vol.

No.

0.014

10908722

0.015

8071485

0.016

6896037

0.017

7128221

0.018

1636332

(20min delay)
Last 1.4¢		Change 0.003(22.7%)		Mkt cap ! $85.87M

Open	High	Low	Value	Volume
1.2¢	1.4¢	1.1¢	$262.0K	21.60M

The CF33, Vaxinia and Oncarlytics Deal, page-1055

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Boss extends June win streak with boosted Alta Mesa extraction rates

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Australia’s gas crisis is here – and dying coal plants aren’t helping

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The CF33, Vaxinia and Oncarlytics Deal, page-1055

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Boss extends June win streak with boosted Alta Mesa extraction rates

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Australia’s gas crisis is here – and dying coal plants aren’t helping

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News